av/celyad-oncology-sa--big.svg

EURONEXT:CYAD

Celyad Oncology

  • Stock

EUR

Last Close

0.46

02/05 08:16

Market Cap

11.14M

Beta: 1.73

Volume Today

1.30K

Avg: 33.32K

PE Ratio

−0.22

PFCF: −0.38

OverviewFinancialsAPI

    Description

    Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA ...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -1-0.52020-12-302022-12-302023-11-092024-04-052024-09-20

    Revenue (Estimate*)

    200K400K600K800K1M1.20M1.40M2020-12-302022-12-302023-11-092024-04-052024-09-20

    *Estimate based on analyst consensus